Point: Impact of prostate-specific antigen velocity on management decisions and recommendations

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 3, 2013, Pages 281-285

  Loeb, Stacy ^a   Carter, H Ballentine ^b  

^a NEW YORK UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER THERAPY; KINETICS; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR BIOPSY;

EID: 84875889881     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0039     Document Type: Article

References (37)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
2. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732.
3. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
4. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-1834.
5. Tang P, Du W, Xie K, et al. Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: racial differences. Prostate 2012;72:173-180.
6. Loeb S, Roehl KA, Catalona WJ, et al. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age? BJU Int 2008;101:817-821.
7. Sun L, Moul JW, Hotaling JM, et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int 2007;99:753-757.
8. Tang P, Sun L, Uhlman MA, et al. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU Int 2011;108:44-48.
9. Mouraviev V, Broadwater G, Sun L, et al. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? Urology 2008;71:1020-1023.
10. Loeb S, Roehl KA, Helfand BT, et al. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol 2010;183:112-116.
11. Wallner LP, Frencher SK, Hsu JW, et al. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. BJU Int, in press.
12. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-135.
13. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-447.
14. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174:2191-2196.
15. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527.
16. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
17. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-2816.
18. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-131.
19. Iremashvili V, Manoharan M, Lokeshwar SD, et al. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int, in press.
20. Carter HB. Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl 2012;14:355-360.
21. Loeb S, Kettermann A, Ferrucci L, et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008;54:1073-1080.
22. Loeb S, Kan D, Yu X, et al. Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy. J Urol 2010;183:1816-1821.
23. Loeb S, Roehl KA, Catalona WJ, et al. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007;177:899-902.
24. Vickers AJ, Till C, Tangen CM, et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103:462-469.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172.
26. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-935.
27. Loeb S, Metter EJ, Carter HB. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103:1636-1637.
28. Fillon M. Study supports PSA velocity risk count. J Natl Cancer Inst 2012;104:1042-1043.
29. Carter HB, Kettermann A, Ferrucci L, et al. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007;70:685-690.
30. Loeb S, Metter EJ, Kan D, et al. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int 2012;109:508-513.
31. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-29.
32. Presti JC, Andriole G, Bahnson RR, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2, 2012. Available at NCCN.org. Accessed June 12, 2012.
33. Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008;71:1016-1019.
34. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009;56:753-760.
35. Park JJ, Chen MH, Loffredo M, et al. Prostate-specific antigen velocity before and after elimination of factors that can confound the prostate-specific antigen level. Int J Radiat Oncol Biol Phys 2012;82:1217-1221.
36. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-132.
37. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182:2232-2241.